Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q1 2020 · 10-Q
Revenue$354.32M$354.32M−1.5% vs Q1 2019 Net Income$9.18M$9.18M−72.0% vs Q1 2019 EPS Diluted$0.11$0.11−71.1% vs Q1 2019 Gross Profit$220,848,000−4.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
Operating Cash Flow$20,814,000−29.4% Free Cash Flowderived$4,295,000−67.9% Margins · derivedGross margin62.3%−1.8 pt vs Q1 2019
Operating margin7.6%−1.3 pt vs Q1 2019
Net margin2.6%−6.5 pt vs Q1 2019
ended Mar 31, 2020 · filed May 7, 2020 · 37 d after period end